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Objective: The seventh TNM Classification of Malignant Tumours will be published in 2009. The International
Association for the Study of Lung Cancer has proposed a revision of the current pathologic staging system. We
illustrated the effects of this new system and pointed out potential problems using a retrospective study of surgical
cases of non–small cell lung cancer at our institution.
Methods: Subjects were 1532 patients for whom current pathologic staging was possible. These data were mi-
grated into the new staging system. The numbers of patients at various stages determined by using the current and
new staging systems were, respectively, as follows: IA (n ¼ 700, n ¼ 700), IB (n ¼ 338, n ¼ 249), IIA (n ¼ 49,
n ¼ 164), IIB (n ¼ 129, n ¼ 116), IIIA (n ¼ 204, n ¼ 234), IIIB (n ¼ 77, n ¼ 17), and IV (n ¼ 35, n ¼ 52).
Prognoses were compared by using the current and the new systems.
Results: By using the new staging system, 5-year survivals by T classifications were as follows: T1a, 82.6%;
T1b, 73.3%; T2a, 63.5%; T2b, 50.1%; T3, 40.6%; and T4, 34.6%. There were significant differences between
the new T1a and T1b (P¼ .0026), T1b and T2a (P¼ .0027), and T2a and T2b (P¼ .0062) classifications. In the
current system 5-year survivals based on pathologic stages were as follows: IA, 84.8%; IB, 72.9%; IIA, 53.8%;
IIB, 53.7%; IIIA, 31.8%; IIIB, 34.0%; and IV, 27.1%. There were significant differences between stages IA and
IB (P< .0001) and stages IIB and IIIA (P ¼ .0006). In the new system these were as follows: IA, 84.8%; IB,
75.2%; IIA, 62.4%; IIB, 52.1%; IIIA, 32.4%; IIIB, 15.2%; and IV, 30.6%. There were significant differences
between stages IA and IB (P ¼ .0004), IB and IIA (P ¼ .0195), IIA and IIB (P ¼ .0257), IIB and IIIA (P ¼
.0040), and IIIA and IIIB (P ¼ .0399).
Conclusion:Although the outcomes for stages IIIB and IV were reversed, the new pathologic staging system was
considered valid based on our single-institution evaluation.
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Staging is important for predicting patient prognosis and se-
lecting appropriate treatment for lung cancers. Although the
current (sixth edition) TNM Classification of Malignant Tu-
mours by the International Union Against Cancer (UICC) is
an excellent staging system, various problems have been in-
dicated for many aspects of lung cancer.1 The next edition of
the TNM Classification of Malignant Tumours, the seventh,
is due to be published in 2009. In preparation for this, the
International Association for the Study of Lung Cancer
(IASLC) established its Lung Cancer Staging Project in
1998 to formulate recommendations for the seventh edi-
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doi:10.1016/j.jtcvs.2008.09.0301180 The Journal of Thoracic and Cardiovascular Sution.2,3 The project has been recognized by the UICC as
the primary source for recommendations for revisions to
the sixth edition of the TNM Classification of Malignant
Tumours. Lung cancer treatments are based on staging,
and changes in staging greatly affect these treatment strate-
gies. For the evaluation of new treatment strategies, there
will be a need for the migration of current data into the new
staging system in most institutions. We migrated current
data for surgical cases of non–small cell lung cancer at our
institution into this new system both to illustrate the effects
of this new system and to point out potential problems.
MATERIALS AND METHODS
The subjects were 1532 surgical patients with non–small cell lung cancer at
pathologic stages I to IV who were seen at our institution from 1984 to 2007.
They underwent resections of tumors with dissection or sampling of lymph no-
des, and T, N, and M classifications could be pathologically evaluated. There
were 369 patients with squamous cell carcinoma, 1061 with adenocarcinoma,
29 with adenosquamous carcinoma, 35 with large cell carcinoma, and 38 with
other types of cancer. The surgical procedures were lobectomy for 1182 pa-
tients, bilobectomy for 66 patients, pneumonectomy for 70 patients, comple-
tion pneumonectomy for 9 patients, segmentectomy for 130 patients, wedge
resection for 74 patients, and 1 other procedure for 1 patient.
The current classification followed the sixth edition of the TNM Classi-
fication of Malignant Tumours.1 The new classification followed the revised
staging system proposed by the IASLC.3 In the new TNM classifications,
tumors that fulfill the definition for T1 and are 2 cm or smaller in the greatestrgery c May 2009
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dimension should be designated T1a, whereas those that are larger than 2 cm
but 3 cm or smaller in the greatest dimension should be designated T1b.
Those tumors that fulfill the present definition of T2 and are 5 cm or smaller
in the greatest dimension become T2a, whereas those that are larger than 5
cm but 7 cm or smaller in the greatest dimension become T2b. Tumor di-
mension of larger than 7 cm becomes a T3 descriptor. Additional tumor nod-
ules in the lobe of the primary tumor become T3, nodules in other ipsilateral
lobes become T4, and nodules in the contralateral lung remain M1. The
presence of malignant pleural effusion, pleural dissemination, or pericardial
disease becomes an M classification. The M category is subdivided into the
following: M1a, which includes the new classifications added to this cate-
gory (ie, patients with pleural nodules or malignant pleural or pericardial ef-
fusion and additional pulmonary nodules in the contralateral lung) and M1b
for those patients with other distant metastases. The existing N classifica-
tions were validated, and no changes are proposed. T2a N1 M0 tumors mi-
grate to stage IIA from stage IIB. T2b N0 M0 tumors migrate to stage IIA
from stage IB. T4 N0 M0 and T4 N1 M0 tumors migrate to stage IIIA from
stage IIIB (Table 1).
Table 2 shows the numbers of patients by T, N, and M classifications in
the current and new staging systems. The numbers of patients classified by
the current and new staging systems were, respectively, as follows: IA (n¼
700, n¼ 700), IB (n¼ 338, n¼ 249), IIA (n¼ 49, n¼ 164), IIB (n¼ 129,
n ¼ 116), IIIA (n ¼ 204, n ¼ 234), IIIB (n ¼ 77, n ¼ 17), and IV (n ¼ 35,
n ¼ 52). Comparisons of prognoses were performed.
All data were not included in the IASLC database. Computed tomo-
graphic analysis of the chest, brain, and upper portion of the abdomen and
bone scintigraphic analysis were performed routinely for the preoperative
evaluation of the extent of disease. Generally, patients were postoperatively
examined at 3-month intervals for 5 years and at 1-year intervals thereafter to
check for recurrence and survival. The median follow-up time was 49
months (range, 0–267 months). Since 1997, induction therapy had routinely
preceded the cases for which the preoperative evaluation was greater than
stage IIIA. Since 1999, video-assisted thoracoscopic surgery was performed
for cases for which the preoperative evaluation was clinical stage I. Since
2002, adjuvant therapy was used routinely for cases for which the postoper-
ative evaluation was greater than stage IIB. Patients with recurrent disease
received chemotherapy, radiotherapy, or both as often as possible. We ob-
tained informed consent from the patients preoperatively for use of clinical
data, and our institutional review board approved this retrospective study.
Survival was determined from the date of surgical intervention until
death from any cause. Survival curves were calculated by using the
Kaplan–Meier method, and differences in survival were evaluated by using
a log-rank test. Statistical calculations were done with Stat View 5.0 (SAS
Institute, Inc, Cary, NC).
RESULTS
The 5-year survivals by T classification in the current
staging system were as follows: T1, 78.7%; T2, 60.9%;
T3, 34.5%; and T4, 36.9 (Table 3). The 5-year survivals
by T classifications in the new staging system were as fol-
lows: T1, 78.5%; T2, 60.2%; T3, 40.6%; and T4, 34.6%
(Table 4). T4 tended to have a worse prognosis than T3 in
the new staging system compared with the current system.The Journal of Thoracic and CThe following are the 5-year survivals by subgroups of T
classifications, which were newly established in the new
staging system: T1a, 82.6%; T1b, 73.3%; T2a, 63.5%;
and T2b, 50.1%. There were significant differences between
the newly established T1a and T1b (P ¼ .0026), T1b and
T2a (P¼ .0027) and T2a and T2b (P¼ .0062) classifications
(Figure 1).
For the N classifications, the 5-year survivals by the cur-
rent staging system were as follows: N0, 77.0%; N1,
54.2%; N2, 28.4%; and N3, 0.0%. There were significant
differences between N0 and N1 (P< .0001), N1 and N2
(P< .0001) and N2 and N3 (P ¼ .0002, Table 3).
The following are the 5-year survivals by subgroups of M
classifications that were newly established in the new stag-
ing system: M0, 68.5%; M1a, 30.0%; and M1b, 25.1%.
TABLE 1. Classifications, proposed TandM categories, and proposed
stage groupings
Sixth edition T/M
classifications Proposed T/M N0 N1 N2 N3
T1 (2 cm) T1a IA IIA IIIA IIIB
T1 (>2–3 cm) T1b IA IIA IIIA IIIB
T2 (5 cm) T2a IB IIA IIIA IIIB
T2 (>5–7 cm) T2b IIA IIB IIIA IIIB
T2 (>7 cm) T3 IIB IIIA IIIA IIIB
T3 invasion IIB IIIA IIIA IIIB
T4 (same lobe nodules) IIB IIIA IIIA IIIB
T4 (extension) T4 IIIA IIIA IIIB IIIB
M1 (ipsilateral lung) IIIA IIIA IIIB IIIB
T4 (pleural effusion) M1a IV IV IV IV
M1 (contralateral lung) IV IV IV IV
M1 (distant) M1b IV IV IV IV
Entries in bold indicate a change from the sixth edition for a particular TNM category.
TABLE 2. Numbers of patients by T, N, and M classifications in the
current and new staging systems
N0 N1 N2 N3 Total
Sixth edition T/M
T1 707 47 73 3 830
T2 345 76 98 6 525
T3 54 21 23 0 98
T4 42 17 18 2 79
M0 1133 158 198 8 1497
M1 15 3 14 3 35
Total 1148 161 212 11 1532
Proposed T/M
T1a 440 15 28 3 486
T1b 268 32 45 1 346
T2a 252 54 70 3 379
T2b 80 23 25 2 130
T3 104 31 41 2 178
T4 4 6 3 0 13
M0 1121 151 200 8 1480
M1a 23 7 7 0 37
M1b 4 3 5 3 15
Total 1148 161 212 11 1532ardiovascular Surgery c Volume 137, Number 5 1181
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(P< .0001) and M1a and M1b (P ¼ .0434, Table 4).
For the current staging system, the 5-year survivals by
stage were as follows: IA, 84.8%; IB, 72.9%; IIA, 53.8%;
IIB, 53.7% (P ¼ .4951); IIIA, 31.8%; IIIB, 34.0% (P ¼
.7812); and IV, 27.1% (Figure 2, A). There was a significant
difference between stages IA and IB (P< .0001) and stages
IIB and IIIA (P¼ .0006). For the new staging system, the 5-
year survivals by stage were as follows: IA, 84.8%; IB,
75.2%; IIA, 62.4%; IIB, 52.1%; IIIA, 32.4%; IIIB,
15.2%; and IV, 30.6%. There were significant differences
between stages IA and IB (P ¼ .0004), IB and IIA (P ¼
.0195), IIA and IIB (P ¼ .0257), IIB and IIIA (P ¼ .0040),
and IIIA and IIIB (P ¼ .0399); (Figure 2, B).
DISCUSSION
Although the current (sixth edition) TNM Classification
of Malignant Tumours by the UICC is an excellent staging
system, various problems have been indicated in many as-
pects for lung cancer.1,4,5 The next edition of the TNM Clas-
sification of Malignant Tumours, the seventh, is due to be
published in 2009. In preparation for this, the IASLC estab-
TABLE 3. Comparisons of overall survival between TNM
classifications by using the sixth edition of TNM classifications
Sixth
edition TNM Deaths/no.
Median
survival (mo)
5-Year
survival (%) P value
T1 120/830 53 78.7 –
T2 166/525 46 60.9 <.0001
T3 58/98 35 34.5 <.0001
T4 38/79 33 36.9 .8373
N0 192/1148 52 77.0 –
N1 60/161 45 54.2 <.0001
N2 122/212 32 28.4 <.0001
N3 8/11 11 0.0 .0002
M0 360/1497 50 68.2 –
M1 22/35 24 27.1 <.0001
Total 382/1532 49 67.3 –
P value: Significance value from log-rank test of survival hazard functions relative to
preceding row.
TABLE 4. Comparisons of overall survival between T and M
classifications by using the new TNM classifications proposed by the
International Association for the Study of Lung Cancer
Proposed
TM Deaths/no.
Median
survival (mo)
5-Year
survival (%)
P
value
T1 122/832 53 78.5 –
T2 162/509 46 60.2 <.0001
T3 90/178 37 40.6 <.0001
T4 8/13 21 34.6 .3343
M0 354/1480 50 68.5 –
M1a 18/37 34 30.0 <.0001
M1b 10/15 10 25.1 .0434
Total 382/1532 49 67.3 –
P value: significance value from log-rank test of survival hazard functions relative to
preceding row.1182 The Journal of Thoracic and Cardiovascular Sulished its Lung Cancer Staging Project in 1998 to bring to-
gether the large databases available worldwide and to
formulate recommendations for the seventh edition that
would be intensively validated.2,3 Analysis of data from
81,015 cases worldwide was performed. The IASLC pro-
posed a revision of the current staging system that was pre-
sented at the 12th World Conference on Lung Cancer. In
addition, the details were published in the Journal of Tho-
racic Oncology.3,6-9 The new staging system was based on
an intensive and validated analysis of the largest database
available to date. It is highly likely that the next edition of
the TNM Classification of Malignant Tumours will be based
on this new staging system.
In our analyses of prognoses by the T classifications, there
were clear differences between T1a and T1b, between T1b
and T2a, and between T2a and T2b, which were new sub-
groups in the new staging system. It has been previously
shown that there are clear differences in prognosis based
on tumor size.10-12 In the new staging system optimal cut
points for tumor size were determined by using ‘‘a running
log-rank test.’’6 Indications for limited operations and the
significance of postoperative adjuvant therapy for T1 and
T2 cases have been discussed.13-16 Furthermore, the detailed
studies of subgroupings in the new staging system are more
useful. In the new staging system, compared with the current
system, T3 tended to show a better prognosis than T4. This
resulted as ipsilateral pulmonary nodules in the same lobe
were changed from T4 to T3 and ipsilateral pulmonary nod-
ules in another lobe were changed from M1 to T4. The prog-
noses for these groups were previously considered to be
good based on the current classification system, and these
changes were considered valid.17,18 In the analyses for prog-
noses by the M classifications, there were differences in
prognosis among M1a, M1b, and M0, which were estab-
lished in the new staging system.8 In the analyses for prog-
noses by stages, there were differences in prognosis between
FIGURE 1. Overall survival based on pathologic T classification sub-
groups proposed by the International Association for the Study of Lung
Cancer. There were significant differences between the newly established
T1a and T1b (P ¼ .0026), T1b and T2a (P ¼ .0027), and T2a and T2b
(P ¼ .0062) classification.rgery c May 2009
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new staging system. These differences were not seen in
the current staging system.
A problem with the new staging system is the reversal of
outcomes for stages IIIB and IV. These trends were also seen
for pathologic staging in the new IASLC staging system.3,9
However, the reason for the reversal was not described. For
the operative cases, the numbers of pathologic stage IIIB and
IV tumors are too small for evaluation. However, the pa-
tients with a good prognosis might be included in stage
IV, especially M1a. In fact, for our patients, there were sig-
nificant differences between M1a and M1b. Contralateral
pulmonary nodules, which are detected by means of imaging
and not proved pathologically, might not be metastatic.17 Pa-
tients with malignant effusion (dissemination) and no distant
metastases might be offered a good prognosis with an oper-
FIGURE 2. Overall survival based on pathologic stage. Survival based on
the sixth edition of the TNM classifications (A) and the new TNM classifi-
cations proposed by the International Association for the Study of Lung
Cancer (B) is shown. The numbers of patients classified by the current
and new staging systems were as follows: IA (n ¼ 700, n ¼ 700), IB
(n ¼ 338, n ¼ 249), IIA (n ¼ 49, n ¼ 164), IIB (n ¼ 129, n ¼ 116), IIIA
(n ¼ 204, n ¼ 234), IIIB (n ¼ 77, n ¼ 17), and IV (n ¼ 35, n ¼ 52). In
the current system there were significant differences between stages IA
and IB (P< .0001) and between stages IIB and IIIA (P ¼ .0006). In the
new staging system there were significant differences between IA and IB
(P ¼ .0004), IB and IIA (P ¼ .0195), IIA and IIB (P ¼ .0257), IIB and
IIIA (P ¼ .0040), and IIIA and IIIB (P ¼ .0399).The Journal of Thoracic and Cation and adjuvant therapy.19-22 Therefore the M1a classifi-
cation might have to be reconsidered.
For pathologic staging proposed by the IASLC, the revi-
sions that focused on the T classifications were reflected well
by the improvements for stages I to III. Although the out-
comes for stages IIIB and IV were reversed, the new patho-
logic staging system was considered valid based on our
single-institution evaluation.
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